https://www.selleckchem.com/products/AZD8931.html
Sodium glucose cotransporter-2inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). We mined the FAERS from 2014q1 to 2019q4 to compare AF reporting for SGLT-2i versus reports for other glucose lowering medications (ATC10 class). Several exclusions were sequentially applied for concomitant medications; diabetes, cardiovascular or renal disease indication
Aimer
Commentaire
Partagez
